現(xiàn)代脂質(zhì)三聯(lián)治療ppt課件(已修改)
2025-01-28 11:38 本頁面
【正文】 現(xiàn)代脂質(zhì)三聯(lián)治療 Introduction Part I Efficacy The Power to Reach Target Key Factor: + Differentiators: LDL Reduction TG HDL LDL/HDL Ratio The Lipid Triad The LDL/HDL Ratio Our Strength, Our Story!! Clear positioning for Lipobay A new perception of efficacy Differentiation to Atorvastatin Fit with our product profile LDL HDL Additional risk factor, especially in diabetics The Lipid Triad Overview TG The Lipid Triad The Ratio The Lipid Triad and Strategic Rationale Part II ? No scientific evidence ? Evidence contradicting this statement ? A marketing hypothesis to build their LDL story ? Creating the perception of the statin with the strongest efficacy It’s logical It’s measurable It’s practicable The Lipid Triad The GP’s Perspective Supporting Data from Landmark Studies Part III 12 10 8 6 4 2 0 % Mortality Placebo Q1 Q2 Q3 Q4 (low HDLincrease) (high HDLincrease) 4S Study CAD Mortality per Quartiles of Increases in HDLCholesterol KJEKSHUS J amp。 PEDERSEN T (unpublished) HDL Intervention Trial (VAHIT) RUBINS HB et al. New Engl J Med 1999。 341:410 0 6 31 4 35 30 25 20 15 10 5 0 5 10 Cholesterol LDLC HDLC Triglycerides Percent change pared to placebo at 1 year Secondary Prevention in 2531 men with low HDLC amp。 LDLC showed a 22% reduction in bined fatal and nonfatal MI HDL Cholesterol as Risk Factor for CHD LRC CPPT (Placebo) MRFIT (usual care) Incidence rate of CHD Incidence rate of CHD 12 10 8 6 4 2 0 100 130 160 190 GORDON DJ et al. Circulation 1989。 79: 8 15. HDL C [mg / dl] 65 55 45 35 LDL Cholesterol mg / dl LDL Cholesterol mg / dl 12 10 8 6 4 2 0 100 130 160 190 0 1 2 3 Framingham Heart Study CAD risk as a function of LDLC and HDLC in men (50 to 70 y) CASTELLI WP. Am J Cardiol 1998。 82:6065 220 160 100 85 65
教學(xué)課件相關(guān)推薦
鄂ICP備17016276號-1